HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16
HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.
Read original at benzingaStocks · News reference
Alpha Tau Medical Treats First Patient In ADMIRE Study, Clinical Trial Evaluating Intratumoral Alpha DaRT For Immunocompromised Patients With Recurrent Cutaneous Squamous Cell Carcinoma
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 12:35 PM
- Checked
- Jul 15, 2026, 12:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses of $(0.13) per share
Read original at benzingaHC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
Read original at benzingaAlpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients
Response RateAmong evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an objective response rate (i.e., systemic complete response plus partial response) of 100%, including four complete responses
Read original at benzinga